CLINICAL UPDATES Non-Hodgkin lymphoma

[21] Morton Lindsay M., 2014, Journal of the National Cancer Institute Monographs, P130, DOI 10.1093/jncimonographs/lgu013

[22] Epidemiology of non-Hodgkin's lymphoma (NHL):: trends, geographic distribution, and etiology [J]. ANNALS OF HEMATOLOGY, 2005, 84 (01) : 1 - 12

[23] National Institute for Health and Care Excellence, 2015, SUSP CANC REC REF NI

[24] Cancers attributable to infection in the UK in 2010 [J]. BRITISH JOURNAL OF CANCER, 2011, 105 : S49 - S56

[25] CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J]. LANCET ONCOLOGY, 2006, 7 (05) : 379 - 391

[26] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J]. LANCET, 2013, 381 (9873) : 1203 - 1210

[27] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J]. LANCET, 2011, 377 (9759) : 42 - 51

[28] Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study [J]. BLOOD, 2008, 112 (13) : 4824 - 4831

[29] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J]. BLOOD, 2007, 109 (05) : 1857 - 1861

[30] Pathogenesis of Human B Cell Lymphomas [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 30, 2012, 30 : 565 - 610

[21] Morton Lindsay M., 2014, Journal of the National Cancer Institute Monographs, P130, DOI 10.1093/jncimonographs/lgu013

[22] Epidemiology of non-Hodgkin's lymphoma (NHL):: trends, geographic distribution, and etiology [J]. ANNALS OF HEMATOLOGY, 2005, 84 (01) : 1 - 12

[23] National Institute for Health and Care Excellence, 2015, SUSP CANC REC REF NI

[24] Cancers attributable to infection in the UK in 2010 [J]. BRITISH JOURNAL OF CANCER, 2011, 105 : S49 - S56

[25] CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group [J]. LANCET ONCOLOGY, 2006, 7 (05) : 379 - 391

[26] Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial [J]. LANCET, 2013, 381 (9873) : 1203 - 1210

[27] Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial [J]. LANCET, 2011, 377 (9759) : 42 - 51

[28] Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study [J]. BLOOD, 2008, 112 (13) : 4824 - 4831

[29] The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP [J]. BLOOD, 2007, 109 (05) : 1857 - 1861

[30] Pathogenesis of Human B Cell Lymphomas [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 30, 2012, 30 : 565 - 610